deltatrials
Unknown PHASE2 NCT00003560

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma

Sponsor: Herbert Irving Comprehensive Cancer Center

Conditions Endometrial Cancer Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer
Interventions carboplatin docetaxel
Updated 5 times since 2017 Last updated: Jan 3, 2014 Started: May 31, 1998

Listed as NCT00003560, this PHASE2 trial focuses on Endometrial Cancer and Fallopian Tube Cancer and remains ongoing. Sponsored by Herbert Irving Comprehensive Cancer Center, it has been updated 5 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

May 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Herbert Irving Comprehensive Cancer Center
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States